State of Michigan Retirement System boosted its position in shares of Becton Dickinson and Co (NYSE:BDX) by 21.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,297 shares of the medical instruments supplier’s stock after purchasing an additional 13,244 shares during the period. State of Michigan Retirement System’s holdings in Becton Dickinson and were worth $18,016,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Smith Shellnut Wilson LLC ADV increased its holdings in Becton Dickinson and by 3.2% during the 1st quarter. Smith Shellnut Wilson LLC ADV now owns 1,305 shares of the medical instruments supplier’s stock worth $300,000 after purchasing an additional 40 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. grew its holdings in shares of Becton Dickinson and by 1.1% in the 2nd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 3,815 shares of the medical instruments supplier’s stock valued at $913,000 after acquiring an additional 40 shares in the last quarter. Capital Bank & Trust Co grew its holdings in shares of Becton Dickinson and by 21.2% in the 1st quarter. Capital Bank & Trust Co now owns 246 shares of the medical instruments supplier’s stock valued at $57,000 after acquiring an additional 43 shares in the last quarter. Schmidt P J Investment Management Inc. grew its holdings in shares of Becton Dickinson and by 0.4% in the 1st quarter. Schmidt P J Investment Management Inc. now owns 12,774 shares of the medical instruments supplier’s stock valued at $2,935,000 after acquiring an additional 47 shares in the last quarter. Finally, Douglas Lane & Associates LLC grew its holdings in shares of Becton Dickinson and by 2.0% in the 2nd quarter. Douglas Lane & Associates LLC now owns 2,443 shares of the medical instruments supplier’s stock valued at $585,000 after acquiring an additional 47 shares in the last quarter. Hedge funds and other institutional investors own 85.44% of the company’s stock.

BDX stock traded up $7.50 during mid-day trading on Friday, hitting $281.34. 1,491,504 shares of the company were exchanged, compared to its average volume of 1,254,232. The business has a 50 day simple moving average of $250.93 and a 200-day simple moving average of $250.95. The company has a current ratio of 0.98, a quick ratio of 0.66 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $76.29 billion, a PE ratio of 84.74, a price-to-earnings-growth ratio of 3.64 and a beta of 0.93. Becton Dickinson and Co has a 1-year low of $197.75 and a 1-year high of $286.72.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.23. The firm had revenue of $4.25 billion during the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a net margin of 6.10% and a return on equity of 15.75%. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the business posted $2.59 earnings per share. Equities research analysts expect that Becton Dickinson and Co will post 10.35 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a dividend of $0.79 per share. The ex-dividend date is Tuesday, September 8th. This represents a $3.16 annualized dividend and a yield of 1.12%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.05%.

In other news, EVP Patrick Kaltenbach sold 1,049 shares of Becton Dickinson and stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $243.20, for a total value of $255,116.80. Following the completion of the sale, the executive vice president now directly owns 12,661 shares in the company, valued at $3,079,155.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.12% of the company’s stock.

Several equities analysts have recently weighed in on the company. William Blair restated an “outperform” rating on shares of Becton Dickinson and in a report on Thursday, July 2nd. Stifel Nicolaus raised their price objective on Becton Dickinson and from $265.00 to $280.00 and gave the company a “buy” rating in a report on Friday, May 8th. Raymond James decreased their price objective on Becton Dickinson and from $290.00 to $265.00 and set an “outperform” rating for the company in a report on Thursday, June 25th. KeyCorp reiterated a “hold” rating on shares of Becton Dickinson and in a research note on Tuesday, May 12th. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Becton Dickinson and in a research note on Friday, May 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $275.06.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: Dividend Aristocrat Index

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.